Renal impairment increases risk of stroke and systemic embolic events and bleeding in
patients with atrial fibrillation. Direct oral anticoagulants (DOACs) have varied dependence …

ABSTRACT Introduction: Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) are at
least as effective as vitamin K antagonists (VKAs) reducing thromboembolism and mortality …

Background: We previously reported exogenous antifactor Xa (FXa) activity as a
pharmacokinetic surrogate marker for edoxaban plasma concentrations. Inhibition of …

Direct acting oral anticoagulants (DOACs) are increasingly used for thromboembolic
prophylaxis in patients with atrial fibrillation (AF). However, there is limited data to evaluate …

Background The antithrombotic effect of direct oral anticoagulants (DOAC) in specific clinical
scenarios is difficult to assess. Objective This study aimed to evaluate the effect of DOAC on …

Crossover between direct oral anticoagulants (DOACs) has been underinvestigated, but
happens frequently in clinical practice. It is still unknown whether DOACs have similar rates …

Background: Atrial fibrillation (AF) stands as the most prevalent cardiac arrhythmia, with
associated risks of stroke and systemic thromboembolism. While vitamin K antagonists …

Purpose Antiplatelet therapy initiated before flow diverter placement is effective for the
prevention of ischemic complications. However, the effectiveness of oral anticoagulant …

Venous thromboembolism (VTE), a common condition affecting hospitalized and ambulatory
patients, is associated with significant morbidity, mortality, and health care costs. 1 The …

Aim of the present study was to investigate the effects of ongoing treatment with DOACs on
time from trauma to surgery and on in-hospital clinical outcomes (blood losses, need for …